Home
Menu

Article Item

Plantar Heel Pain with Focus on Plantar Fasciopathy

Jul 27, 2026, 08:18 by Daniel Wang, DO, Abenezer Amare, DO, Bhargavi Madhu, DO

 

Case Stem

A 52-year-old female postal worker presents to her primary care physician with a four-month history of right heel pain. She describes the pain as sharp and stabbing, and it is localized to the bottom of her heel near the arch. The pain is most severe when she takes her first steps in the morning. She often rates it as 8 out of 10 on a visual analog scale (VAS), decreasing the rating to 4-5 out of 10 after walking for several minutes. The pain worsens again at the end of her workday. This occurs after prolonged standing and walking on her mail delivery route. She denies history of trauma and constitutional symptoms and fever. The patient reports minimal relief from over-the-counter ibuprofen and acetaminophen.

Patient Medical History: The patient has type 2 diabetes mellitus (prescribed metformin, HbA1c 6.8%), hypertension (takes lisinopril), and obesity (BMI of 34 kg/m²). As a mail carrier, she spends 6–8 hours per day on her feet on concrete. Self-treatment with rest, ice, and shoe changes has provided no significant improvement.

Examination: Point tenderness is found at the anteromedial calcaneus; pain is exacerbated by passive ankle/toe dorsiflexion. Ankle dorsiflexion is limited to 5° (right) and 10° (left). No erythema, warmth, or swelling is present. Neurovascular exam is intact; antalgic gait demonstrates she is favoring the right heel.

Right foot X-ray: A small calcaneal spur is found at the plantar fascial insertion; no fracture or other bony abnormality is seen.

 

Key Questions

1. What clinical features distinguish plantar fasciitis from other causes? What is the differential diagnosis for plantar heel pain?

Plantar fasciitis is the most common cause of heel pain, representing more than 1 million U.S. visits per year.1–4 It presents with plantar heel pain (often medial) that is worst with first weight-bearing steps after rest (especially morning).1–5 It often improves after initial ambulation but worsens again with prolonged activity.1–5 A common finding is point tenderness at the anteromedial calcaneus (plantar fascia insertion).2–4 Pain is exacerbated by passive dorsiflexion of the ankle and toes (windlass test).2–5

Other diagnoses to consider: Calcaneal stress fracture, tarsal tunnel syndrome, Baxter nerve entrapment, heel fat pad syndrome, plantar warts, and inflammatory arthropathies should also be considered.3–5

  • Calcaneal stress fracture: Diffuse calcaneal pain worsening with activity, no morning improvement; MRI or bone scan may be needed to differentiate3,6
  • Tarsal tunnel syndrome: Compression of posterior tibial nerve causing medial heel pain with burning or tingling radiating to the plantar foot; Tinel's sign positive posterior to medial malleolus3,5
  • Baxter nerve entrapment (inferior calcaneal nerve): Medial plantar heel pain with burning or paresthesias, pain slightly more distal and lateral than plantar fasciitis, worse later in day rather than morning3,5
  • Heel fat pad syndrome: Deep central heel pain reproduced by direct compression, worse with impact; improves with cushioning5
  • Plantar warts: Hyperkeratotic lesion with black seed dots disrupting skin lines; pain with direct compression; managed with salicylic acid, cryotherapy, or other destructive therapies5
  • Inflammatory arthropathies (reactive arthritis, psoriatic arthritis): Bilateral heel pain from enthesitis, morning stiffness lasting longer than 30 minutes, improves with movement. Look for back pain, psoriasis, uveitis, dactylitis, or recent gastrointestinal or genitourinary infection; evaluate with inflammatory markers and imaging.5,7

This case is most consistent with plantar fasciitis given the morning step-start pain, point tenderness at the anteromedial calcaneal tubercle, limited ankle dorsiflexion, positive windlass test, and absence of neurologic symptoms.

 

2. What is the pathophysiology of plantar fasciitis? What risk factors does this patient have for developing this condition?

The plantar fascia (plantar aponeurosis) arises from the medial calcaneal tubercle and courses distally to the metatarsophalangeal level.3 During gait, toe dorsiflexion tensions the fascia (windlass mechanism), supporting the medial longitudinal arch and optimizing push-off efficiency.3

Although pathogenesis is multifactorial, plantar fasciitis results from repetitive mechanical overload producing microtears near the plantar medial fascial origin.3,7 Histopathology demonstrates degenerative fasciopathy—collagen degeneration, fiber disorganization, increased mucoid ground substance, and calcification.3 This is more common than findings of acute inflammation, which is why the term plantar fasciopathy is increasingly preferred,2,7 though inflammatory mediators may also contribute.7

This patient's key risk factors include the following.

  • Ankle dorsiflexion ≤ 0°: This is among the strongest biomechanical risk factors (OR 23.3 [95% CI, 4.3–124.4] for ≤ 0° vs. > 10°);8 here 5° on the symptomatic side increases plantar fascia strain.
  • BMI 34 kg/m²: Obesity (BMI > 30) significantly increases the odds of plantar fasciitis (OR 5.6 [95% CI, 1.9–16.6]).3,8
  • Occupational load: Spending 6–8 hours per day on concrete perpetuates repetitive microtrauma (OR 3.6 [95% CI, 1.3–10.1] for prolonged weight-bearing work).8
  • Age 52 years. The patient’s age falls within the typical middle-aged range (most common in ages 45–64).3 Diabetes mellitus is a weaker, less consistent risk factor but sometimes still contributes.7,9

 

3. Given the clinical diagnosis of plantar fasciitis, what is the role of imaging in this patient's evaluation?

Plantar fasciitis is primarily a clinical diagnosis; imaging is unnecessary when a thorough history and physical exam is conducted.1–5 Plain radiographs have limited diagnostic value. Calcaneal spurs are a frequent incidental finding and do not confirm or exclude plantar fasciitis.3,5 Their main utility is to exclude stress fracture, tumor, or other bony pathology when the diagnosis is unclear.3,6 Imaging is reserved for: (1) failure to improve with conservative therapy, (2) atypical presentation, or (3) concern for alternative diagnosis.3,6

After about 3 months of symptoms or treatment failure, ultrasonography can be a cost-effective next step.2,6 Plantar fascia thickness > 4 mm (symptomatic cases often 5–7 mm vs. normal 2–4 mm) with hypoechogenicity near the calcaneal insertion supports the diagnosis; dynamic ultrasound examination can also evaluate for tears.1,3 MRI (highly sensitive, shows T2 signal increase and thickening at calcaneal origin) is reserved for diagnostic uncertainty, concern for alternative pathology, or lack of access to ultrasound.3,6 The MRI findings can be nonspecific and seen in asymptomatic individuals.6 Bone scintigraphy can differentiate plantar fasciitis (focal uptake at plantar fascial insertion) from calcaneal stress fracture (fracture line or diffuse uptake).1,6

For this patient, radiographs were appropriate to exclude bony pathology. No further imaging is indicated now; ultrasonography is reasonable if symptoms persist after an adequate course of conservative management.2,6

 

4. What are the initial conservative treatment options for plantar fasciitis? What is the evidence supporting their use?

Conservative treatment is the cornerstone of management. With proper treatment, approximately 80%–90% of patients improve within 12 months,2,4 though one study of 174 patients found that 80.5% still had some degree of symptoms at 1-year follow-up, with a mean symptom duration of 725 days among those who eventually resolved.10

  • Activity modification: Reduce or avoid prolonged standing, walking on hard surfaces, and high-impact exercise.1,3 For this mail carrier, workplace accommodations (route modification, cushioned footwear, scheduled sitting breaks) are essential.
  • Stretching and formal physical therapy: Stretching is among the highest-yield interventions.3,11 Plantar fascia–specific and Achilles/gastrocnemius stretching are recommended in addition to a formal progressive overloading focused physical therapy program.3,11
  • Foot orthoses (prefabricated devices comparable to custom orthoses): These devices reduce plantar fascia strain and provide short-term pain reduction.3,11 Taping offers short-term benefit with lower-quality evidence.11
  • Nonsteroidal anti-inflammatory drugs: These can provide symptomatic relief, but current research does not support a disease modifying effect and randomized controlled trials (RCTs) are limited.3
  • Overnight splints: These maintain ankle dorsiflexion to reduce morning step pain; benefit has been shown in chronic or recalcitrant cases, although adherence is key.3,11

 

5. What are the next treatment options if the above conservative management treatments fail?

Corticosteroid injections (CSIs) provide short-term (<1 month) pain reduction vs. placebo (MD –6.38 [95% CI, –11.13 to –1.64]; 5 studies, 350 participants), but this benefit is not sustained at 1–6 months (MD –3.47 [95% CI, –8.43 to 1.48]).9 In a meta-analysis of 47 RCTs (2,989 patients), CSIs outperformed foot orthoses or autologous blood injection at 0–6 weeks, but this advantage did not persist beyond 6 weeks.12 An RCT of 82 patients showed ultrasound-guided dexamethasone produced significant pain relief at 4 weeks (NNT 2.93) but no benefit beyond 4 weeks.13

There are risks involved with CSIs, the most common being injection site pain.3 Plantar fascia rupture occurs in about 2.4% and is more common after multiple injections (mean of 2.63 injections).3 A Cochrane review of 21 trials found 2 ruptures and 3 injection-site infections among 699 steroid-arm participants.9 Other complications include fat pad atrophy, skin depigmentation, and peripheral nerve injury.3,9

Clinical recommendation:

For this patient, where 8 weeks of conservative therapy failed, CSI can be considered for short-term relief to facilitate stretching compliance. The patient should be counselled that relief is temporary (~4 weeks);9,13 there is a small but real risk of rupture especially with repeated injections,3,9 and extracorporeal shock wave therapy (ESWT) or platelet-rich plasma (PRP) may offer more durable benefit.14,15 Continuing conservative measures for 4–6 weeks or proceeding directly to ESWT is also reasonable.

 

6. The patient now returns to your clinic at 12 weeks with continued plantar fascia pain rated 5/10. She has been compliant with her stretching exercises and prefabricated orthoses. What role does ESWT have in the treatment of plantar fasciitis?

ESWT applies pulsatile high-pressure sound waves to promote biological healing of degenerative plantar fascia.3 Delivered as focused (f-ESWT) or radial (r-ESWT), both types are used clinically.14

Efficacy of ESWT

A meta-analysis of 9 RCTs (935 participants) showed ESWT reduced pain vs. placebo (SMD 1.01 [95% CI, –0.01 to 2.03]; p = 0.05).16 A systematic review of 11 RCTs (658 patients) found moderate evidence for improved pain and function.17 In an RCT of 100 patients, ESWT produced lower visual analogue scores than CSI at 6 months (2.1 vs. 2.9; p < 0.001).3 A Food and Drug Administration-approved multicenter RCT (n = 250) demonstrated 69.2% heel pain reduction with f-ESWT vs. 34.5% placebo (p = 0.0027); clinical success rate 50%–65%.18

ESWT vs. CSI: A meta-analysis of 16 studies (n = 1,121) found ESWT superior to CSI at 3 months for pain (standardized mean difference [SMD] –0.6), fascia thickness (SMD –0.4), and function (SMD 0.27), and at 6 months for pain (SMD –0.81) and function (SMD 0.67), indicating ESWT is more effective than CSI at medium-term follow-up.19

Safety: ESWT is safe. The most common adverse events are temporary local pain and slight erythema.18,19 A typical protocol is 3 sessions of 2,000 impulses weekly.18

Clinical recommendation for this patient

ESWT is recommended for this patient (chronic plantar fasciitis >3 months, failed conservative care). Evidence favors ESWT over CSI for medium- to long-term outcomes with minimal adverse events.19 The patient should be counselled that improvement may take several weeks and optimal results are seen at 3–6 months post-treatment.18,19 Ultimately, depending on the patient's goals and pain tolerance, this is a shared decision-making process. ESWT is a very viable option before CSI.

 

7. The patient inquires about PRP injections after hearing a friend has had success with it. What is the evidence for PRP in treating plantar fasciitis? How does it compare to other discussed treatments?

PRP is derived from the patient's own blood and contains concentrated growth factors thought to promote tissue healing by stimulating collagen production, angiogenesis, and remodeling of degenerative fascia.15

PRP is thought to be inferior to CSI for short-term (<1 month) pain relief but possibly superior in the medium to long term.15,20 A meta-analysis of 15 trials (n=811) showed no advantage at 1 month (American Orthopaedic Foot and Ankle Society [AOFAS] SMD 0.98, p = 0.4), but significant improvement at 12 months (SMD –2.73, p = 0.009).15 VAS also improved with PRP at 3, 6, and 12 months.15

A multicenter double-blind RCT (n = 115) found that 84.4% of patients receiving PRP had pain improve ≥ 25% at 12 months vs. 55.6% of patients receiving CSI (p = 0.003).21 A separate meta-analysis of 24 RCTs (1,653 participants) confirmed PRP superior to CSI for VAS at 3 months (p = 0.03) and 6 months (p < 0.001), though the difference was not statistically significant at 1 and 12 months (p = 0.08); AOFAS scores favored PRP at 3, 6, and 12 months.22

Unlike CSI (temporary anti-inflammatory effect), PRP promotes tissue regeneration via growth factors stimulating collagen production, angiogenesis, and remodeling.15 Corticosteroids also carry the risk of plantar fascia rupture, fat pad atrophy, or skin depigmentation.15,22 In terms of fascia thickness, no significant differences were found between PRP and CSI at 1–6 months.22 In a single-arm prospective study of 85 patients, PRP reduced thickness from 6.6 to 4.1 mm at 6 weeks (p < 0.001).23

Safety/Limitations: PRP is relatively safe (autologous, minimal allergic risk), with the most common adverse event being injection-site pain.15,21,22 Limitations include the high risk of bias in many studies and variability in preparation protocols.15 PRP is typically not covered by insurance.

Clinical recommendation for this patient:

PRP is an appropriate option for this patient after experiencing four months of chronic plantar fasciitis and failing conservative care. They should be counselled on the following.

  • PRP can have superior medium- to long-term outcomes vs. CSI (3–12 months), particularly for functional improvement.15,21,22
  • It does not offer immediate pain relief. Rather, improvement begins typically at 6–12 weeks but can significantly vary.
  • PRP promotes tissue healing and has a favorable safety profile.15,21,22
  • Cost and insurance coverage may be limiting factors.

 

8. The patient's symptoms persist at 6 months despite trying ESWT. She is frustrated. She inquires about surgical options. When is surgery appropriate and indicated for plantar fasciitis? What are the surgical options and their outcomes?

Surgery is considered after ≥ 6–12 months of comprehensive conservative management in patients with persistent, severe symptoms who have exhausted nonoperative options (stretching, orthoses, physical therapy, injections, ESWT) and in whom the diagnosis is confirmed.1,3,4

Indications for surgery include the following.

  • Symptoms lasting 6–12 months or more despite comprehensive conservative and nonoperative treatment.1,3
  • Pain is significantly limiting activities of daily living and quality of life.
  • Nonoperative options (e.g., stretching, orthoses, physical therapy, injections, ESWT) have been exhausted.1,3,4
  • The diagnosis is confirmed and alternative causes have been excluded.

Minimally invasive / percutaneous options:

  • TenJet (HydroResection): Uses a high-velocity saline jet to ablate degenerative tissue under ultrasound guidance without thermal energy. It can be performed in the office and has a rapid recovery. Evidence in tendinopathy shows significant pain and function improvement at one year.24 Plantar fasciitis-specific data remain limited to small observational studies.24
  • Tenex Health TX (Percutaneous Ultrasonic Tenotomy): Uses ultrasonic energy to debride degenerative fascia via a small-bore needle under ultrasound guidance and local anesthesia. Systematic reviews confirm decreased pain and improved function for plantar fasciitis with minimal adverse effects.24
  • Topaz MicroDebrider (coblation): Delivers bipolar radiofrequency energy through a small needle array to ablate degenerative plantar fascia tissue and stimulate healing via controlled inflammation and collagen remodeling and can be performed percutaneously or as an open adjunct.25,26 A systematic review and meta-analysis found significant VAS and AOFAS improvements, and the open technique demonstrated superior early outcomes vs. the percutaneous approach.25,26 This technique avoids formal fasciotomy.

Surgical options:

  • Partial plantar fasciectomy: Releases the medial band of the plantar fascia via open, mini-open, or endoscopic technique. Patient satisfaction ranges from 48.8–89.5%.3
  • Endoscopic plantar fasciotomy: One RCT (n = 30) showed improved Foot Function Index at 12 months (p = 0.033) and VAS at 24 months (p = 0.001) vs. nonoperative care; more patients returned to running or jumping (p = 0.04).27

 

References

1. Buchbinder R. Plantar fasciitis. N Engl J Med. 2004;350:2159-66. doi:10.1056/NEJMcp032745

2. Trojian T, Tucker AK. Plantar fasciitis. Am Fam Physician. 2019;99:744-50.

3. Cooper MT. Common painful foot and ankle conditions: a review. JAMA. 2023;330:2285-94. doi:10.1001/jama.2023.23906

4. Goff JD, Crawford R. Diagnosis and treatment of plantar fasciitis. Am Fam Physician. 2011;84:676-82.

5. Tu P. Heel pain: diagnosis and management. Am Fam Physician. 2018;97(2):86-93.

6. Tafur M, Bencardino JT, Roberts CC, et al. ACR Appropriateness Criteria® chronic foot pain. J Am Coll Radiol. 2020;17(11S):S391-S402. doi:10.1016/j.jacr.2020.09.015

7. Rabadi D, Seo S, Wong B, et al. Immunopathogenesis, early detection, current therapies and prevention of plantar fasciitis. Int Immunopharmacol. 2022;110:109023. doi:10.1016/j.intimp.2022.109023

8. Riddle DL, Pulisic M, Pidcoe P, Johnson RE. Risk factors for plantar fasciitis: a matched case-control study. J Bone Joint Surg Am. 2003;85:872-7. doi:10.2106/00004623-200305000-00015

9. David JA, Sankarapandian V, Christopher PR, et al. Injected corticosteroids for treating plantar heel pain in adults. Cochrane Database Syst Rev. 2017;6:CD009348. doi:10.1002/14651858.CD009348.pub2

10. Hansen L, Krogh TP, Ellingsen T, Bolvig L, Fredberg U. Long-term prognosis of plantar fasciitis: a 5- to 15-year follow-up study of 174 patients with ultrasound examination. Orthop J Sports Med. 2018;6(3):2325967118757983. doi:10.1177/2325967118757983

11. Martin RL, Davenport TE, Reischl SF, et al. Heel pain–plantar fasciitis revision 2014. J Orthop Sports Phys Ther. 2014;44(11):A1-A33. doi:10.2519/jospt.2014.0303

12. Whittaker GA, Munteanu SE, Menz HB, et al. Corticosteroid injection for plantar heel pain: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20(1):378. doi:10.1186/s12891-019-2749-z

13. McMillan AM, Landorf KB, Gilheany MF, et al. Ultrasound guided corticosteroid injection for plantar fasciitis. BMJ. 2012;344:e3260. doi:10.1136/bmj.e3260

14. Lippi L, Folli A, Moalli S, et al. Efficacy and tolerability of extracorporeal shock wave therapy in patients with plantar fasciopathy: a systematic review with meta-analysis and meta-regression. Eur J Phys Rehabil Med. 2024;60(5):832-46. doi:10.23736/S1973-9087.24.08136-X

15. Hohmann E, Tetsworth K, Glatt V. Platelet-rich plasma versus corticosteroids for the treatment of plantar fasciitis: a systematic review and meta-analysis. Am J Sports Med. 2021;49:1381-93. doi:10.1177/0363546520937293

16. Sun J, Gao F, Wang Y, et al. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. Medicine (Baltimore). 2017;96(15):e6621. doi:10.1097/MD.0000000000006621

17. Melese H, Alamer A, Getie K, et al. Extracorporeal shock wave therapy on pain and foot functions in subjects with chronic plantar fasciitis: systematic review of randomized controlled trials. Disabil Rehabil. 2022;44(18):5007-14. doi:10.1080/09638288.2021.1928775

18. Gollwitzer H, Saxena A, DiDomenico LA, et al. Clinically relevant effectiveness of focused extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: a randomized, controlled multicenter study. J Bone Joint Surg Am. 2015;97:701-8. doi:10.2106/JBJS.M.01331

19. Cortés-Pérez I, Moreno-Montilla L, Ibáñez-Vera AJ, et al. Efficacy of extracorporeal shockwave therapy, compared to corticosteroid injections, on pain, plantar fascia thickness and foot function in patients with plantar fasciitis: a systematic review and meta-analysis. Clin Rehabil. 2024;38(8):1023-43. doi:10.1177/02692155241253779

20. Shetty SH, Dhond A, Arora M, Deore S. Platelet-rich plasma has better long-term results than corticosteroids or placebo for chronic plantar fasciitis: randomized control trial. J Foot Ankle Surg. 2019;58(1):42-6. doi:10.1053/j.jfas.2018.07.006

21. Peerbooms JC, Lodder P, den Oudsten BL, et al. Positive effect of platelet-rich plasma on pain in plantar fasciitis: a double-blind multicenter randomized controlled trial. Am J Sports Med. 2019;47:3238-46. doi:10.1177/0363546519877181

22. Zuo A, Gao C, Jia Q, et al. Platelet-rich plasma versus corticosteroids in the treatment of plantar fasciitis: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2025;104:613-21. doi:10.1097/PHM.0000000000002677

23. Kumar S, Channaveera C, Sethi S, Wadhwa RK, Anand V. To evaluate efficacy of intralesional platelet rich plasma in patients with plantar fasciitis. J Am Podiatr Med Assoc. 2026;116(2):24161. doi:10.7547/24-161

24. Maag L, Linder S, Hackett L, et al. Effectiveness of percutaneous needle tenotomy for tendinopathies: a systematic review. Sports Health. 2025;17:834-42. doi:10.1177/19417381241275659

25. Tay KS, Ng YC, Singh IR, Chong KW. Open technique is more effective than percutaneous technique for TOPAZ radiofrequency coblation for plantar fasciitis. Foot Ankle Surg. 2012;18:287-92. doi:10.1016/j.fas.2012.05.001

26. Domingo-Marques S, Nieto-García E, Fernández-Erhling N, et al. Efficacy of radiofrequency by the Topaz technique for chronic plantar fasciopathy: systematic review and meta-analysis. J Clin Med. 2025;14(8):2843. doi:10.3390/jcm14082843

27. Johannsen F, Konradsen L, Herzog R, et al. Endoscopic fasciotomy for plantar fasciitis provides superior results when compared to a controlled non-operative treatment protocol: a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2020;28:3301-8. doi:10.1007/s00167-020-05855-3

Close Nav